drugset / Trial / NCT02261467

A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

NCT02261467 ↗

Phase 3 Completed 421 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a safety and efficacy study of onabotulinumtoxinA in subjects with forehead and glabellar facial rhytides (frown lines).

Timeline

Start
2014-10-21
Primary completion
2015-06-04
Completion
2016-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — Other

Indications

No indication recorded.